Variability of the impact of adverse events on physicians’ decision making

Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody—Associated Vasculitis

(2013) Kirsten de Groot   ANNALS OF INTERNAL MEDICINE

Breast Cancer Screening

(2013) Allen Kachalia et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

PML and rheumatology: The contribution of disease and drugs

(2011) E. S. MOLLOY   CLEVELAND CLINIC JOURNAL OF MEDICINE

Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases

(2011) A. Bharat et al.   ARTHRITIS CARE & RESEARCH

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

(2010) Rachel B. Jones et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Review article: Progress of treatment in ANCA-associated vasculitis

(2009) DAVID JAYNE   NEPHROLOGY

The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

(2008) Eric J. Boren et al.   JOURNAL OF AUTOIMMUNITY

A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines

(2008) Y. Tamimoto et al.   RHEUMATOLOGY